dl-3-butylphthalide
Phase 3Small molecule
dl-3-butylphthalide is one of 25 small molecule programs targeting Randomized. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Randomized
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Yondelis
AApotex Inc.
Phase 3
Rituxan
RochePhase 2
Zytiga
Johnson & JohnsonPhase 2
Erleada
Johnson & JohnsonPhase 2
Clomid
FerringPhase 2
Casodex
IIstituto Clinico Humanitas
Phase 2
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for dl-3-butylphthalide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFudan University